Avidity Biosciences, Inc. - Common Stock (RNA)

Historical Holders from Q2 2020 to Q3 2025

Symbol
RNA on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
149,544,182
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
160,908,041
Holdings value
$7,009,352,759
% of all portfolios
0.011%
Number of holders
268
Number of buys
190
Number of sells
-70
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Avidity Biosciences, Inc. - Common Stock (RNA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 9.57% $575,984,900 13,219,759 The Vanguard Group 30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/ 7.1% $426,459,326 9,787,912 T. Rowe Price Associates, Inc. 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 8.1% $299,543,317 9,684,556 Wellington Management Group LLP 31 Mar 2025
RA CAPITAL MANAGEMENT, L.P. 5.9% $376,489,721 8,641,031 RA Capital Management, L.P. 30 Sep 2025
BlackRock, Inc. 6.4% -13.8% $376,086,262 -$17,916,333 8,631,771 -4.5% BlackRock, Inc. 30 Sep 2025
JANUS HENDERSON GROUP PLC 5.5% -47.3% $582,654,041 -$446,149,257 8,224,930 -43.4% JANUS HENDERSON GROUP PLC 28 Nov 2025
RTW INVESTMENTS, LP 3.1% $204,173,813 4,686,110 RTW Investments, LP 27 Oct 2025
FMR LLC 2.1% -86% $128,911,093 -$809,934,537 2,958,712 -86.3% FMR LLC 31 Oct 2025

Institutional Holders of Avidity Biosciences, Inc. - Common Stock (RNA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 160,908,041 $7,009,352,759 +$1,158,003,579 $43.57 268
2025 Q2 135,973,420 $3,861,676,519 +$69,697,401 $28.4 205
2025 Q1 133,409,309 $3,962,056,176 +$178,442,627 $29.52 218
2024 Q4 127,638,993 $3,712,638,686 -$78,035,782 $29.08 234
2024 Q3 126,231,192 $5,796,026,453 +$574,015,774 $45.93 240
2024 Q2 111,913,147 $4,571,667,339 +$938,038,576 $40.85 191
2024 Q1 89,252,994 $2,277,667,387 +$376,305,703 $25.52 156
2023 Q4 75,910,042 $687,025,653 -$46,186,576 $9.05 142
2023 Q3 81,744,893 $521,542,443 -$6,429,051 $6.38 142
2023 Q2 82,383,646 $913,636,020 +$45,839,329 $11.09 140
2023 Q1 75,916,643 $1,165,169,505 +$49,763,836 $15.35 138
2022 Q4 71,661,062 $1,590,188,145 +$426,293,719 $22.19 148
2022 Q3 53,433,471 $872,653,344 -$22,171,694 $16.33 121
2022 Q2 52,143,220 $757,668,637 +$70,638,105 $14.53 107
2022 Q1 47,057,452 $869,011,980 +$27,227,715 $18.47 98
2021 Q4 45,418,262 $1,079,557,657 +$3,680,968 $23.77 104
2021 Q3 44,395,070 $1,093,343,381 +$240,851,131 $24.63 108
2021 Q2 34,505,931 $852,616,782 +$16,849,564 $24.71 93
2021 Q1 33,888,914 $739,147,936 +$60,802,116 $21.81 97
2020 Q4 30,963,803 $790,224,311 +$74,813,975 $25.52 82
2020 Q3 27,022,951 $755,460,115 +$43,834,764 $28.15 67
2020 Q2 25,458,553 $701,864,000 +$701,864,000 $28.26 52